Novartis AG (NVS) Competitors & Peers
The 5 largest companies in the same industry as Novartis AG, by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| LLY | Peer | $1,411.95 | P/E 45.8RSI 68Cap 1.33 T |
| JNJ | Peer | $282.11 | P/E 42.8RSI 64Cap 679.1 B |
| ABBV | Peer | $293.30 | P/E 50.4RSI 62Cap 518.2 B |
| MRK | Peer | $148.76 | P/E 150.3RSI 54Cap 367.4 B |
| AZN | Peer | $189.39 | P/E 26.8RSI 68Cap 288.8 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- REGNCompetitor
Novartis competes directly in the ophthalmology space (e.g., Lucentis and Beovu) against Eylea.
Model-inferred, unverified — treat as a lead, not evidence - ALNYPartner
Alnylam-Novartis Leqvio (inclisiran) for hypercholesterolemia.
Model-inferred, unverified — treat as a lead, not evidence - ERASPartner
Erasca co-develops combinations with Novartis MEK inhibitors.
Model-inferred, unverified — treat as a lead, not evidence - OCSPartner
Oculis in-licensed OCS-02 (licofelanem) TNF-alpha antibody droplet tech from Novartis.
Model-inferred, unverified — treat as a lead, not evidence - VERACompetitor
Vera's atacicept competes with Novartis's pipeline therapies for IgA nephropathy treatment.
Model-inferred, unverified — treat as a lead, not evidence - VEEVSupplier
Novartis uses Veeva Vault as a primary clinical/regulatory platform.
Model-inferred, unverified — treat as a lead, not evidence